Bundibugyo Ebolavirus GP Antikörper

Produktnummer ABIN7794767

Dieser HEK-293 Cells Monoklonal Antikörper detektiert spezifisch Bundibugyo Ebolavirus GP in ELISA, BP, Func, IEM und Neut. Es zeigt Reaktivität gegenüber Proben von Bundibugyo Virus (BDBV).

Kurzübersicht für Bundibugyo Ebolavirus GP Antikörper (ABIN7794767)

Target: Bundibugyo Ebolavirus GP

Reaktivität: Bundibugyo Virus (BDBV)

Wirt: HEK-293 Cells

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: ELISA, Blocking Peptide (BP), Functional Studies (Func), Immunoelectron Microscopy (IEM), Neutralization (Neut)

Klon: BDBV-335

Produktdetails

Verwendungszweck: Anti-Bundibugyo Ebolavirus, GP (Clone BDBV-335)-Purified No Carrier Protein

Spezifität: BDBV-335 activity is directed against the glycan cap of Bundibugyo ebolavirus (BDBV) glycoprotein (GP) between residues 274 and 282. BDBV-335 binds equally well to both native GP and a recombinant GP secreted to the extracellular space during infection (sGP). Antigen Distribution BDBV-335 activity is directed against the glycan cap of Bundibugyo ebolavirus (BDBV) glycoprotein (GP) between residues 274 and 282. BDBV-335 binds equally well to both native GP and a recombinant GP secreted to the extracellular space during infection (sGP). Background Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90 % 1. Three Ebola species are responsible for lethal outbreaks Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV). The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell, endosomal entry, and membrane fusion1. GP is composed of two subunits, GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop, transmembrane domain, and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus 1,2,3 1,2,3. BDBV-335 is a glycan cap mAb isolated from B cells of a survivor of the 2007 Uganda BDBV outbreak3. Peripheral blood mononuclear cells from the survivor were transformed with Epstein-Barr virus, CpG, and additional supplements. Subsequently, cell supernatants were screened by ELISA for binding to GPs from BDBV, EBOV, or MARV filoviruses. Positive cells were fused with HMMA2.5 myeloma cells by electrofusion and cloned by single-cell fluorescence-activated cell sorting. According to EM structural analysis, BDBV-335 binds further down the glycan cap than BDBV-41, a mAb in the same binding group3. BDBV-335 targets a region in GP1 that is centered on the glycan cap between residues 274 and 282.

Aufreinigung: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Reinheit: >=90 % monomer by analytical SEC and SDS-Page

Isotyp: IgG1 kappa

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Konservierungsmittel: Without preservative

Lagerung: 4 °C,-80 °C

Informationen zur Lagerung: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Antigendetails

Target: Bundibugyo Ebolavirus GP

Substanzklasse: Viral Protein